HC Wainwright Comments on Unity Biotechnology, Inc.’s Q1 2024 Earnings (NASDAQ:UBX)

Unity Biotechnology, Inc. (NASDAQ:UBX) – Stock analysts at HC Wainwright issued their Q1 2024 EPS estimates for Unity Biotechnology in a research report issued on Tuesday, April 16th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of ($0.57) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Unity Biotechnology’s Q2 2024 earnings at ($0.59) EPS, Q3 2024 earnings at ($0.62) EPS, Q4 2024 earnings at ($0.64) EPS and FY2028 earnings at $0.29 EPS.

Unity Biotechnology Stock Performance

Unity Biotechnology stock opened at $1.51 on Wednesday. The stock has a 50-day simple moving average of $1.66 and a 200-day simple moving average of $1.78. The company has a market capitalization of $25.35 million, a P/E ratio of -0.51 and a beta of 0.87. Unity Biotechnology has a fifty-two week low of $1.50 and a fifty-two week high of $3.82.

Institutional Trading of Unity Biotechnology

Large investors have recently bought and sold shares of the business. Arete Wealth Advisors LLC purchased a new stake in shares of Unity Biotechnology during the 1st quarter worth approximately $142,000. Jane Street Group LLC purchased a new stake in Unity Biotechnology during the fourth quarter worth $37,000. Schonfeld Strategic Advisors LLC acquired a new stake in Unity Biotechnology in the fourth quarter valued at $38,000. Two Sigma Investments LP purchased a new position in shares of Unity Biotechnology in the first quarter valued at $32,000. Finally, Commonwealth Equity Services LLC raised its stake in shares of Unity Biotechnology by 53.1% during the 1st quarter. Commonwealth Equity Services LLC now owns 24,512 shares of the company’s stock worth $39,000 after buying an additional 8,499 shares during the last quarter. Institutional investors and hedge funds own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.